Compare 8x8 Inc (EGHT) vs Nuwellis Inc (NUWE) Price & Performance

EGHT (8x8, Inc.) trades at $1.89, down 12.9% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $27.21M in 2025 despite revenue of $715.07M, though recent quarters have beaten EPS estimates. Positive news includes AI product launches and industry awards, while analyst consensus is mixed with 39% buy ratings.

Outlook hinges on profitability improvement; projected net income of $2M in 2026 offers potential upside, but high debt and thin margins pose risks. Stock sentiment is cautiously optimistic due to innovation, yet volatility and competitive pressures require monitoring for sustained growth.

Nuwellis (NUWE) trades at $3.22, up 15% in the last 24 hours, following a recent 35:1 reverse stock split executed on June 26, 2026. The medical technology company shows a mixed financial picture with a strong gross margin of 65.47% but significant net losses and negative profitability ratios. Recent news highlights expansion in pediatric care, new patent awards, and a $6 million public offering closed in June 2026 to fund operations. Technical indicators are predominantly bearish, with moving averages signaling strong selling pressure.

The outlook remains challenging due to persistent operating losses and negative cash flow, offset by strategic pediatric market expansion and new product innovation. Investment opportunity hinges on the company's ability to translate its high gross margin and recent capital raise into sustainable revenue growth and eventual profitability. Key risks include continued cash burn, execution of commercial strategy, and reliance on financing activities to fund operations.